entertainment -WSS

entertainment

author：leisure time 2025-09-30 09:29:47 - browse：1616

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： As AI in medicine takes off, can 'human in the loop' prevent harm?

WSS

FDA advisers back CAR

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Clinicians often fail to acknowledge the pain caused by long Covid

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Stroke rates rising, especially in working

RaDonda Vaught links Vanderbilt hospital issues to patient death

hotspot

entertainment

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

FDA advisers back CAR

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: CAR

Bright Health sells Medicare Advantage business to Molina

Why we need mandatory labeling of GMO products

Duchenne breakthrough therapy leaves behind pioneering families

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

New air purifier tech could be key to improving indoor air quality

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

focus

Some medical students still think black patients feel less pain

The world needs the new pandemic treaty

First U.S. drug developed to treat liver disease MASH is approved

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Protect nursing home residents from future pandemics

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

leisure time

focus

hotspot